Medibiofarma announces first subject dosed in phase Ib multiple ascending dose study of MBF-118, a new PPARg covalent partial agonist, in healthy volunteers

Navarra – July 2021– Medibiofarma S.L., a clinical-stage biotechnology company developing a portfolio of new therapies for the treatment of cancer and non-cancer diseases today announced the first subject dosed in the Phase Ib clinical trial of MBF-118. This compound has successfully completed the initial dose-escalation, single dose phase. The objectives of the phase Ib trial are the continued evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of MBF-118 after oral intake in healthy volunteers.

The release as fetched from its publisher. medibiofarma.com ↗